AR104720A1 - Moduladores de ccr2 - Google Patents
Moduladores de ccr2Info
- Publication number
- AR104720A1 AR104720A1 ARP160101482A ARP160101482A AR104720A1 AR 104720 A1 AR104720 A1 AR 104720A1 AR P160101482 A ARP160101482 A AR P160101482A AR P160101482 A ARP160101482 A AR P160101482A AR 104720 A1 AR104720 A1 AR 104720A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- cycloalkyl
- heteroaryl
- aryl
- Prior art date
Links
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 title 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 title 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 12
- 125000001072 heteroaryl group Chemical group 0.000 abstract 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 9
- 125000003118 aryl group Chemical group 0.000 abstract 8
- 125000001424 substituent group Chemical group 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 229910052757 nitrogen Inorganic materials 0.000 abstract 7
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 7
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 abstract 6
- 229910003827 NRaRb Inorganic materials 0.000 abstract 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 5
- 125000005842 heteroatom Chemical group 0.000 abstract 5
- 229910052760 oxygen Inorganic materials 0.000 abstract 5
- 229910052717 sulfur Inorganic materials 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 102000004497 CCR2 Receptors Human genes 0.000 abstract 2
- 108010017312 CCR2 Receptors Proteins 0.000 abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 abstract 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 abstract 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 abstract 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000001769 aryl amino group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000005241 heteroarylamino group Chemical group 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000001422 pyrrolinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 1
- 150000003536 tetrazoles Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
- Amplifiers (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Compuestos que son moduladores del receptor de CCR2 y son útiles en composiciones farmacéuticas, métodos para el tratamiento de enfermedades y trastornos que involucran la activación patológica de receptores de CCR2. Reivindicación 1: Un compuesto caracterizado porque que tiene la fórmula (1); o una sal aceptable farmacéuticamente, hidrato, estereoisómero o rotámero del mismo; donde A es C(R⁵)(R⁶) o N(R⁵) los subíndices m y n son en forma independiente entre sí enteros de 0 a 2, y m + n es £ 3; R¹ se selecciona entre el grupo que consiste en arilo, aril-C₁₋₄ alquilo, heteroarilo y heteroaril-C₁₋₄ alquilo, donde la porción heteroarilo tiene entre 1 - 3 heteroátomos como miembros del anillo que se seleccionan entre N, O y S; y donde dichos grupos o porciones arilo y heteroarilo están sustituidos opcionalmente con entre 1 y 5 sustituyentes Rˣ; R² se selecciona entre el grupo que consiste en H, C₁₋₈ alquilo, C₃₋₈ cicloalquilo, C₃₋₈ cicloalquil-C₁₋₄ alquilo, arilo, aril-C₁₋₄ alquilo, heteroarilo y heteroaril-C₁₋₄ alquilo, donde la porción heteroarilo tiene entre 1 - 3 heteroátomos como miembros del anillo que se seleccionan entre N, O y S; y donde dichos grupos o porciones arilo y heteroarilo están sustituidos opcionalmente con entre 1 y 4 sustituyentes Rˣ; u opcionalmente, R¹ y R² se combinan con el átomo de nitrógeno al cual cada uno está unido para formar un anillo monocíclico de 6 a 11 miembros o anillo fusionado bicíclico - heterocíclico o heteroarilo, donde el grupo -NR¹R² está además opcionalmente sustituido con entre 1 y 4 sustituyentes Rˣ; R³ se selecciona entre el grupo que consiste en H, C₁₋₈ alquilo, C₃₋₈ cicloalquilo y C₃₋₈ cicloalquil-C₁₋₄ alquilo, cada uno de los cuales está opcionalmente sustituido con entre 1 - 3 sustituyentes Rʸ; R⁴ se selecciona entre el grupo que consiste en H, C₁₋₈ alquilo opcionalmente sustituido con 1 a 2 Rʸ, y -CO₂H; R⁵ se selecciona entre el grupo que consiste en C₁₋₈ alquilo, C₁₋₈ alcoxi, C₃₋₈ cicloalquilo, C₃₋₈ cicloalquiloxi, C₃₋₈ cicloalquil-C₁₋₄ alquilo, C₁₋₈ alquilamino, di-C₁₋₈ alquilamino, arilo, ariloxi, arilamino, aril-C₁₋₄ alquilo, heteroarilo, heteroariloxi, heteroarilamino y heteroaril-C₁₋₄ alquilo, cada uno de los cuales está opcionalmente sustituido con entre 1 y 5 sustituyentes Rᶻ; R⁶ se selecciona entre el grupo que consiste en H, F, OH, C₁₋₈ alquilo y C₁₋₈ alcoxi, donde los grupos C₁₋₈ alquilo y C₁₋₈ alcoxi están sustituidos opcionalmente con entre 1 y 3 sustituyentes Rᶻ; u opcionalmente, R⁵ y R⁶ se unen para formar un anillo cicloalquilo espirocíclico de 5 ó 6 miembros que es opcionalmente insaturado, y tiene un grupo arilo fusionado que está opcionalmente sustituido con entre 1 y 4 sustituyentes Rᶻ; cada Rˣ se selecciona en forma independiente entre el grupo que consiste en halógeno, -CN, -Rᶜ, -CO₂Rᵃ, -CONRᵃRᵇ, -C(O)Rᵃ, -OC(O)NRᵃRᵇ, -NRᵇC(O)Rᵃ, -NRᵇC(O)₂Rᶜ, -NRᵃ-C(O)NRᵃRᵇ, NRᵃC(O)NRᵃRᵇ, -NRᵃRᵇ, -ORᵃ, -O-X¹-ORᵃ, -O-X¹-NRᵃRᵇ, -O-X¹-CO₂Rᵃ, -O-X¹-CONRᵃRᵇ, -X¹-ORᵃ, -X¹-NRᵃRᵇ, -X¹-CO₂Rᵃ, -X¹-CONRᵃRᵇ, -SF₅, -S(O)₂NRᵃRᵇ, y arilo o heteroarilo de 5 ó 6 miembros, donde cada X¹ es un C₁₋₄ alquileno; cada Rᵃ y Rᵇ se selecciona en forma independiente entre hidrógeno, C₁₋₈ alquilo, y C₁₋₈ haloalquilo, o cuando está unido al mismo átomo de nitrógeno se puede combinar con el átomo de nitrógeno para formar un anillo de 5 ó 6 miembros con entre 0 a 2 heteroátomos adicionales como miembros del anillo que se seleccionan entre N, O ó S, y opcionalmente sustituido con oxo; cada Rᶜ se selecciona en forma independiente entre el grupo que consiste en C₁₋₈ alquilo, C₁₋₈ haloalquilo y C₃₋₆ cicloalquilo; y opcionalmente cuando dos sustituyentes Rˣ están sobre átomos adyacentes, se combinan para formar un anillo carbocíclico fusionado de 5 ó 6 miembros, y donde los grupos arilo o heteroarilo están sustituidos opcionalmente con 1 - 3 miembros que se seleccionan entre halógeno, hidroxilo, C₁₋₄ alquilo, C₁₋₄ alcoxi, C₁₋₄ haloalquilo, y C₁₋₄ haloalcoxi; cada Rʸ se selecciona en forma independiente entre el grupo que consiste en halógeno, -CN, -Rᶠ, -CO₂Rᵈ, -CONRᵈRᵉ, -C(O)Rᵈ, -OC(O)NRᵈRᵉ, -NRᵉC(O)Rᵈ, -NRᵉC(O)₂Rᶠ, -NRᵈC(O)NRᵈRᵉ, -NRᵈC(O)NRᵈRᵉ, -NRᵈRᵉ, -ORᵈ, y -S(O)₂NRᵈRᵉ; donde cada Rᵈ y Rᵉ se selecciona en forma independiente entre hidrógeno, C₁₋₈ alquilo, y C₁₋₈ haloalquilo, o cuando está unido al mismo átomo de nitrógeno se puede combinar con el átomo de nitrógeno para formar un anillo de 5 ó 6 miembros con entre 0 a 2 heteroátomos adicionales como miembros del anillo que se seleccionan entre N, O ó S; cada Rᶠ se selecciona en forma independiente entre el grupo que consiste en C₁₋₈ alquilo, C₁₋₈ haloalquilo y C₃₋₆ cicloalquilo; cada Rᶻ se selecciona en forma independiente entre el grupo que consiste en halógeno, -CN, -Rⁱ, -CO₂Rᵍ, -CONRᵍRʰ, -C(O)Rᵍ, -OC(O)NRᵍRʰ, NRʰC(O)Rᵍ, -NRʰC(O)₂Rⁱ, -NRᵍC(O)NRᵍRʰ, -NRᵍRʰ-, -ORᵍ, -S(O)₂NRᵍRʰ, -X¹-Rʲ, -X¹-NRᵍRʰ, -X¹-CONRᵍRʰ, -X¹-NRʰC(O)Rᵍ, -NHRʲ, -NHCH₂Rʲ, y tetrazol; donde cada Rᵍ y Rʰ se selecciona en forma independiente entre hidrógeno, C₁₋₈ alquilo, C₃₋₆ cicloalquilo y C₁₋₈ haloalquilo, o cuando está unido al mismo átomo de nitrógeno se puede combinar con el átomo de nitrógeno para formar un anillo de 5 ó 6 miembros con entre 0 a 2 heteroátomos adicionales como miembros del anillo que se seleccionan entre N, O ó S y está opcionalmente sustituido con uno o dos oxo; cada Rⁱ se selecciona en forma independiente entre el grupo que consiste en C₁₋₈ alquilo, C₁₋₈ haloalquilo y C₃₋₆ cicloalquilo; y cada Rʲ se selecciona entre el grupo que consiste en C₃₋₆ cicloalquilo, pirrolinilo, piperidinilo, morfolinilo, tetrahidrofuranilo, y tetrahidropiranilo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562164957P | 2015-05-21 | 2015-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR104720A1 true AR104720A1 (es) | 2017-08-09 |
Family
ID=57320660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160101482A AR104720A1 (es) | 2015-05-21 | 2016-05-20 | Moduladores de ccr2 |
Country Status (27)
Country | Link |
---|---|
US (4) | US9783540B2 (es) |
EP (1) | EP3297438B1 (es) |
JP (1) | JP6841771B2 (es) |
KR (1) | KR102622891B1 (es) |
CN (1) | CN108135168B (es) |
AR (1) | AR104720A1 (es) |
AU (1) | AU2016263579B2 (es) |
BR (1) | BR112017024555A2 (es) |
CA (1) | CA2985194C (es) |
CY (1) | CY1124918T1 (es) |
DK (1) | DK3297438T3 (es) |
ES (1) | ES2904252T3 (es) |
HR (1) | HRP20220028T1 (es) |
HU (1) | HUE060376T2 (es) |
IL (1) | IL255509B (es) |
LT (1) | LT3297438T (es) |
MA (1) | MA42133A (es) |
MX (1) | MX2017014375A (es) |
NZ (1) | NZ737399A (es) |
PL (1) | PL3297438T3 (es) |
PT (1) | PT3297438T (es) |
RS (1) | RS62809B1 (es) |
RU (1) | RU2726206C2 (es) |
SI (1) | SI3297438T1 (es) |
TW (1) | TWI733670B (es) |
WO (1) | WO2016187393A1 (es) |
ZA (1) | ZA201707966B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9046025B2 (en) | 2013-06-07 | 2015-06-02 | GM Global Technology Operations LLC | Selective catalytic reduction device monitoring system |
EP3297438B1 (en) | 2015-05-21 | 2021-10-20 | ChemoCentryx, Inc. | Ccr2 modulators |
WO2017165125A1 (en) * | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
KR20220130249A (ko) | 2016-05-26 | 2022-09-26 | 리커리엄 아이피 홀딩스, 엘엘씨 | Egfr 억제제 화합물 |
EP3641794A4 (en) * | 2017-06-23 | 2021-03-24 | The Trustees of Columbia University in the City of New York | METHODS FOR THE PREVENTION AND TREATMENT OF DISEASES CHARACTERIZED BY SYNAPTIC DYSFUNCTION AND NEURODEGENERENCE, INCLUDING ALZHEIMER'S DISEASE |
EP3687525A4 (en) * | 2017-09-25 | 2021-10-13 | ChemoCentryx, Inc. | POLYTHERAPY USING A CHEMIOKIN RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1 / PD-L1 INHIBITOR |
US10758540B2 (en) | 2017-10-11 | 2020-09-01 | Chemocentryx, Inc. | Treatment of focal segmental glomerulosclerosis with CCR2 antagonists |
US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
CN112105353B (zh) * | 2018-01-08 | 2024-04-19 | 凯莫森特里克斯股份有限公司 | Ccr2拮抗剂治疗实体瘤的方法 |
US11292785B2 (en) * | 2018-02-02 | 2022-04-05 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Nitrogen-containing benzoheterocycle compound comprising carboxylic acid group, preparation method and use thereof |
WO2020033791A1 (en) | 2018-08-09 | 2020-02-13 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
US20220204608A1 (en) | 2019-04-17 | 2022-06-30 | Hiroshima University | Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination |
KR20220034829A (ko) | 2019-07-10 | 2022-03-18 | 케모센트릭스, 인크. | Pd-l1 억제제로서의 인단 |
EP4003356A1 (en) * | 2019-07-30 | 2022-06-01 | Edvince AB | Mek inhibitor for treatment of stroke |
CN112773805B (zh) * | 2019-11-11 | 2024-05-10 | 中国科学院脑科学与智能技术卓越创新中心 | 缺血性脑损伤的新型治疗药物 |
CN111139294A (zh) * | 2020-01-06 | 2020-05-12 | 中国药科大学 | Fdps在制备治疗非酒精性脂肪性肝炎药物中的应用 |
US11045453B1 (en) * | 2020-03-10 | 2021-06-29 | Redhill Biopharma Ltd. | Serine protease inhibitor for treating coronavirus infection |
CN111423454B (zh) * | 2020-04-24 | 2021-06-22 | 苏州大学 | 哌嗪类化合物及其在制备趋化因子受体ccr2拮抗剂中的应用 |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6627629B2 (en) * | 2000-06-30 | 2003-09-30 | Bristol-Myers Squibb Pharma | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity |
ES2271063T3 (es) | 2000-08-17 | 2007-04-16 | MERCK & CO., INC. | Moduladores ciclopentilos de la actividad del receptor de la quimioquina. |
RU2004100839A (ru) | 2001-07-02 | 2005-06-20 | Астразенека Аб (Se) | Производные пиперидина полезные в качестве модуляторов активности рецепторов хемокинов |
AU2003231114B8 (en) * | 2002-04-29 | 2008-08-14 | Merck Sharp & Dohme Corp. | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
AU2003223755B2 (en) | 2002-04-29 | 2008-08-21 | Merck Sharp & Dohme Corp. | Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity |
JO2479B1 (en) | 2002-04-29 | 2009-01-20 | ميرك شارب اند دوم ليمتد | Rates for the activity of the chemokine receptor of tetrahydrobranyl cycloneptil tetrahydrobredo predine |
US20060030582A1 (en) | 2002-04-29 | 2006-02-09 | Demartino Julie | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
US7491737B2 (en) | 2002-10-30 | 2009-02-17 | Merck & Co., Inc. | Heterarylpiperidine modulators of chemokine receptor activity |
AU2004215409B2 (en) | 2003-02-24 | 2008-11-20 | Merck Sharp & Dohme Corp. | Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity |
AU2004222336B2 (en) | 2003-03-18 | 2010-06-03 | Merck Sharp & Dohme Corp. | Amino cyclobutylamide modulators of chemokine receptor activity |
AU2004231087B2 (en) * | 2003-04-15 | 2007-01-04 | Merck Sharp & Dohme Corp. | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors |
JP2006523704A (ja) | 2003-04-17 | 2006-10-19 | メルク エンド カムパニー インコーポレーテッド | ケモカイン受容体活性ヘテロサイクリックシクロペンチルテトラヒドロイソキノリンおよびテトラヒドロピリドピリジンのモジュレーター |
WO2004110376A2 (en) | 2003-06-06 | 2004-12-23 | Merck & Co., Inc. | Ccr-2 antagonists for treatment of neuropathic pain |
WO2005044264A1 (en) | 2003-10-27 | 2005-05-19 | Merck & Co., Inc. | Ccr-2 antagonist salt |
AR045875A1 (es) | 2003-10-27 | 2005-11-16 | Merck & Co Inc | Procedimiento para la preparacion del antagonista ccr-2 |
JP2007519633A (ja) * | 2004-01-02 | 2007-07-19 | メルク エンド カムパニー インコーポレーテッド | アルキルアミノ、アリールアミノおよびスルホンアミドシクロペンチルアミド系のケモカイン受容体活性調節剤 |
WO2005080371A1 (en) * | 2004-02-12 | 2005-09-01 | Merck & Co., Inc. | Amino heterocyclic modulators of chemokine receptor activity |
KR100837019B1 (ko) | 2004-05-11 | 2008-06-10 | 인사이트 코포레이션 | 케모카인 수용체 조절제로서3-(4-헤테로아릴사이클로헥실아미노)사이클로펜탄카복스아마이드 |
UY29219A1 (es) | 2004-11-22 | 2006-04-28 | Incyte Corp | Sales de la n-(2- (((3r)-1-(trans-4-hidroxi-4-(6-metoxipiridin-3-il)-cilohexil) pirrolidin-3-il)amino)-2-oxoetil)-3- (trifluorometil) benzamida |
AU2006204038A1 (en) | 2005-01-06 | 2006-07-13 | Merck & Co., Inc. | Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders |
CN100364643C (zh) * | 2006-05-11 | 2008-01-30 | 同济大学 | 一种从排气中吸附回收净化有机物的方法和装置 |
US8519135B2 (en) | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
US7671062B2 (en) * | 2006-07-28 | 2010-03-02 | Bristol-Myers Squibb Company | Modulators of chemokine receptor activity, crystalline forms and process |
BRPI0812913B8 (pt) | 2007-06-18 | 2021-05-25 | Merck Sharp & Dohme | anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos |
PL2175859T3 (pl) | 2007-07-12 | 2012-09-28 | Chemocentryx Inc | Skondensowane heteroarylopirydylo- i fenylo-benzenosulfonamidy jako modulatory CCR2 do leczenia zapalenia |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
ES2592216T3 (es) | 2008-09-26 | 2016-11-28 | Dana-Farber Cancer Institute, Inc. | Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos |
PA8853001A1 (es) | 2008-12-10 | 2010-07-27 | Janseen Pharmaceutica N V | 4-azentidinil-1-heteroaril-ciclohexanol antagonista del ccr2 |
JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille | Pd−1抗体およびpd−l1抗体ならびにその使用 |
JP5685580B2 (ja) | 2009-04-16 | 2015-03-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap | Ccr2の4−アゼチジニル−1−ヘテロアリール−シクロヘキサンアンタゴニスト |
CN102459227B (zh) | 2009-04-17 | 2014-08-20 | 詹森药业有限公司 | Ccr2的4-氮杂环丁烷基-1-苯基-环己烷拮抗剂 |
PT3091012T (pt) | 2009-12-17 | 2018-06-27 | Centrexion Therapeutics Corp | Antagonistas do receptor ccr2 e suas utilizações |
EP2534158B1 (en) | 2010-02-09 | 2014-01-08 | Bristol-Myers Squibb Company | Benzylpyrrolidinone derivatives as modulators of chemokine receptor activity |
WO2011141474A1 (en) | 2010-05-12 | 2011-11-17 | Boehringer Ingelheim International Gmbh | Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
US8642622B2 (en) | 2010-06-16 | 2014-02-04 | Bristol-Myers Squibb Company | Piperidinyl compound as a modulator of chemokine receptor activity |
MX2012014934A (es) | 2010-06-17 | 2013-05-20 | Janssen Pharmaceutica Nv | Antagonistas de ciclohexilacetindinilo del receptor de la citocina quimioatrayente 2. |
AU2012226890B2 (en) * | 2011-03-10 | 2016-10-06 | Daiichi Sankyo Company, Limited | Dispiropyrrolidine derivative |
SG11201402603WA (en) | 2011-11-28 | 2014-06-27 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
US8822460B2 (en) | 2012-04-06 | 2014-09-02 | Janssen Pharmaceutica Nv | Fused cyclopentyl antagonists of CCR2 |
BR112014028826B1 (pt) | 2012-05-15 | 2024-04-30 | Bristol-Myers Squibb Company | Uso de nivolumab ou pembrolizumabe |
RU2689760C2 (ru) | 2012-05-31 | 2019-05-30 | Дженентек, Инк. | Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов |
CN105051065A (zh) | 2012-06-22 | 2015-11-11 | 索伦托治疗有限公司 | 与ccr2结合的抗原结合蛋白 |
US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
WO2015002754A2 (en) | 2013-06-21 | 2015-01-08 | Zenith Epigenetics Corp. | Novel bicyclic bromodomain inhibitors |
MX2016000510A (es) | 2013-07-16 | 2016-04-07 | Genentech Inc | Metodos para tratar cancer utilizando antagonistas de union al eje pd-1 e inhibidores de tigit. |
KR102232153B1 (ko) | 2013-08-20 | 2021-03-24 | 머크 샤프 앤드 돔 코포레이션 | Pd-1 길항제와 디나시클립의 조합을 사용한 암의 치료 |
BR112016004194A8 (pt) | 2013-09-04 | 2020-02-11 | Bristol Myers Squibb Co | compostos úteis como imunomoduladores |
TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
KR102330652B1 (ko) | 2014-09-11 | 2021-11-23 | 브리스톨-마이어스 스큅 컴퍼니 | Pd-1/pd-l1 및 cd80 (b7-1)/pd-li 단백질/단백질 상호작용의 마크로시클릭 억제제 |
US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
EP3297438B1 (en) | 2015-05-21 | 2021-10-20 | ChemoCentryx, Inc. | Ccr2 modulators |
WO2017165125A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer |
US10195188B2 (en) | 2016-06-13 | 2019-02-05 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
US10251888B2 (en) | 2016-06-13 | 2019-04-09 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
AU2017289038B2 (en) | 2016-06-27 | 2021-07-22 | Chemocentryx, Inc. | Immunomodulator compounds |
JP2020517256A (ja) | 2017-04-19 | 2020-06-18 | エルスター セラピューティクス, インコーポレイテッド | 多重特異性分子およびその使用 |
US20190275015A1 (en) | 2017-09-25 | 2019-09-12 | Chemocentryx, Inc. | Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor |
EP3687525A4 (en) | 2017-09-25 | 2021-10-13 | ChemoCentryx, Inc. | POLYTHERAPY USING A CHEMIOKIN RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1 / PD-L1 INHIBITOR |
CN112105353B (zh) | 2018-01-08 | 2024-04-19 | 凯莫森特里克斯股份有限公司 | Ccr2拮抗剂治疗实体瘤的方法 |
US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
WO2019144098A1 (en) | 2018-01-22 | 2019-07-25 | Bristol-Myers Squibb Company | Compositions and methods of treating cancer |
US20200297708A1 (en) | 2019-03-19 | 2020-09-24 | Chemocentryx, Inc. | Combination Therapy Using a Chemokine Receptor 2 (CCR2) Antagonist and a PD-1 and/or PD-L1 Inhibitor |
-
2016
- 2016-05-19 EP EP16797279.3A patent/EP3297438B1/en active Active
- 2016-05-19 KR KR1020177036757A patent/KR102622891B1/ko active IP Right Grant
- 2016-05-19 PL PL16797279T patent/PL3297438T3/pl unknown
- 2016-05-19 PT PT167972793T patent/PT3297438T/pt unknown
- 2016-05-19 MX MX2017014375A patent/MX2017014375A/es unknown
- 2016-05-19 JP JP2017560247A patent/JP6841771B2/ja active Active
- 2016-05-19 HU HUE16797279A patent/HUE060376T2/hu unknown
- 2016-05-19 BR BR112017024555A patent/BR112017024555A2/pt not_active Application Discontinuation
- 2016-05-19 AU AU2016263579A patent/AU2016263579B2/en active Active
- 2016-05-19 DK DK16797279.3T patent/DK3297438T3/da active
- 2016-05-19 MA MA042133A patent/MA42133A/fr unknown
- 2016-05-19 US US15/158,713 patent/US9783540B2/en active Active
- 2016-05-19 SI SI201631442T patent/SI3297438T1/sl unknown
- 2016-05-19 RS RS20220041A patent/RS62809B1/sr unknown
- 2016-05-19 LT LTEPPCT/US2016/033210T patent/LT3297438T/lt unknown
- 2016-05-19 NZ NZ737399A patent/NZ737399A/en unknown
- 2016-05-19 RU RU2017144651A patent/RU2726206C2/ru active
- 2016-05-19 ES ES16797279T patent/ES2904252T3/es active Active
- 2016-05-19 CN CN201680029546.7A patent/CN108135168B/zh active Active
- 2016-05-19 WO PCT/US2016/033210 patent/WO2016187393A1/en active Application Filing
- 2016-05-19 HR HRP20220028TT patent/HRP20220028T1/hr unknown
- 2016-05-19 CA CA2985194A patent/CA2985194C/en active Active
- 2016-05-20 AR ARP160101482A patent/AR104720A1/es active IP Right Grant
- 2016-05-20 TW TW105115844A patent/TWI733670B/zh active
-
2017
- 2017-08-31 US US15/692,811 patent/US10464934B2/en active Active
- 2017-11-07 IL IL255509A patent/IL255509B/en active IP Right Grant
- 2017-11-23 ZA ZA2017/07966A patent/ZA201707966B/en unknown
-
2019
- 2019-09-23 US US16/579,488 patent/US20200121688A1/en not_active Abandoned
-
2021
- 2021-06-24 US US17/357,427 patent/US12054484B2/en active Active
-
2022
- 2022-01-19 CY CY20221100047T patent/CY1124918T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR104720A1 (es) | Moduladores de ccr2 | |
AR119651A1 (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington | |
AR109788A1 (es) | Compuestos de benzo[b]tiofeno como agonistas de sting | |
AR108812A1 (es) | Proceso para preparar un derivado de piridona policíclica sustituida y cristal del mismo | |
AR102492A1 (es) | Cromanos sustituidos y métodos para su uso | |
AR089527A1 (es) | Inhibidores de bromodominios | |
AR110038A1 (es) | Compuestos inhibidores de egfr; composición farmacéutica que lo comprende; métodos para mejorar o tratar un cáncer; método para inhibir la replicación de un crecimiento maligno o un tumor; métodos para inhibir la actividad del egfr; y usos de los compuestos | |
AR112834A1 (es) | Derivados de rapamicina | |
AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
ES2626801T3 (es) | Compuestos de triazolopiridina como inhibidores de pde10a | |
AR091193A1 (es) | HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg | |
AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
AR092809A1 (es) | 3,5-diaminopirazol como inhibidor de quinasa | |
AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
AR095359A1 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
AR099789A1 (es) | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina | |
AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
AR102258A1 (es) | Compuestos de quinolina y quinazolina | |
AR107955A1 (es) | Derivados de piridino- / pirimidino-piridina, con actividad herbicida | |
AR089753A1 (es) | Derivados de amida heterociclicos como antagonistas del receptor p2x7 | |
AR102544A1 (es) | Compuestos derivados de dihidrohidantoína como herbicidas | |
AR098818A1 (es) | Derivados de oxindol, preparación de los mismos y uso terapéutico de los mismos | |
AR088596A1 (es) | Compuestos de bencilamina sustituidos | |
AR104539A1 (es) | Compuestos cíclicos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |